Lucid Diagnostics

Yahoo Finance • 2 days ago

Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth while targeting Medicare and commercial payer wins

Earnings Call Insights: Lucid Diagnostics Inc. (LUCD) Q4 2025 MANAGEMENT VIEW * CEO Lishan Aklog reported that "our EsoGuard test volume in the fourth quarter was 3,664. That exceeds our target range that we've articulated regularly of... Full story

Yahoo Finance • 2 days ago

Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary

Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Achieved record Q4 test volume of 3,664, exceeding the target range of 2,500 to 3,000, driven by improved sales team productivity a... Full story

Yahoo Finance • 3 days ago

Pre-Market Earnings Report for March 26, 2026 : CMC, DOO, SCVL, DBI, LOVE, LUCD, ABOS, CGTX, RMTI

The following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Commercial Metals Company (CMC)is reporting for the quarter ending F... Full story

Yahoo Finance • 4 months ago

Lucid Diagnostics Non-GAAP EPS of -$0.10 misses by $0.01, revenue of $1.21M misses by $0.14M

* Lucid Diagnostics press release [https://seekingalpha.com/pr/20303744-lucid-diagnostics-provides-business-update-and-reports-third-quarter-2025-financial-results] (LUCD [https://seekingalpha.com/symbol/LUCD]): Q3 Non-GAAP EPS of -$0.10... Full story

Yahoo Finance • 7 months ago

Lucid Diagnostics dips after pricing $25M stock offering

* Lucid Diagnostics (NASDAQ:LUCD [https://seekingalpha.com/symbol/LUCD]) fell over 17% premarket on Wednesday after it priced a public offering of 25 million shares at $1.00 each. * Underwriters also have a 30-day option to buy up to 3... Full story

Yahoo Finance • 7 months ago

Lucid Diagnostics announces proposed public offering of common stock

* Lucid Diagnostics (NASDAQ:LUCD [https://seekingalpha.com/symbol/LUCD]) announced on Tuesday its intention to offer shares [https://seekingalpha.com/pr/20226999-lucid-diagnostics-announces-proposed-public-offering-of-common-stock] of co... Full story

Yahoo Finance • 7 months ago

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia Lucid Diagnostics to collaborate with PAVmed as a strategic and equity partner on the t... Full story

Yahoo Finance • 7 months ago

PAVmed Q2 2025 slides reveal dramatic cost reduction amid Lucid Diagnostics growth

Introduction & Market Context PAVmed Inc. (NASDAQ:PAVM) presented its Q2 2025 business update on August 14, highlighting significant cost reduction measures and progress across its subsidiaries. The medical technology company, currently t... Full story

Yahoo Finance • 7 months ago

Electrify Expo Returns to the Bay Area August 23-24 with Expanded Automotive Lineup Just One Month Before EV Tax Credits End

Unique to Alameda Point, the Launch Party lane will allow attendees to feel the thrill factor of EVsLucid will offer public demos of their much-anticipated Gravity modelFlying car from Pivotal, hosted by SoFly, will be on displayTesla will... Full story

Yahoo Finance • 7 months ago

LUCID DIAGNOSTICS INC (NASDAQ:LUCD) Reports Q2 2025 Earnings In Line with Estimates, Narrower Loss Than Expected

LUCID DIAGNOSTICS INC (NASDAQ:LUCD [https://www.chartmill.com/stock/quote/LUCD]) reported its second-quarter 2025 financial results, with revenue and earnings per share (EPS) closely aligning with analyst expectations. The company processe... Full story

Yahoo Finance • 8 months ago

PAVmed granted 180-day extension to meet Nasdaq minimum bid price

NEW YORK - PAVmed Inc. (NASDAQ:PAVM), a commercial-stage medical technology company with a market capitalization of $10.17 million, announced Wednesday it has received a 180-day extension from Nasdaq to regain compliance with the $1.00 min... Full story

Yahoo Finance • 8 months ago

Lucid says meeting scheduled to determine Medicare coverage for cancer test

[Immunotherapy: A New Frontier in Cancer Detection and Treatment] bymuratdeniz Cancer test maker Lucid Diagnostics (NASDAQ:LUCD [https://seekingalpha.com/symbol/LUCD]), majority owned by PavMed (NASDAQ:PAVM [https://seekingalpha.com/symbo... Full story

Yahoo Finance • 3 years ago

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK, June 28, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, tod... Full story

Yahoo Finance • 4 years ago

Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results

Conference call to be held today at 4:30 PM EDT NEW YORK, May 11, 2022--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned... Full story

Yahoo Finance • 4 years ago

PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously... Full story